Pasquali Renato, Pelusi Carla, Genghini Silvia, Cacciari Mauro, Gambineri Alessandra
Division of Endocrinology, Department of Internal Medicine and Gastroenterology, S. Orsola-Malpighi Hospital, University of Bologna, Italy.
Hum Reprod Update. 2003 Jul-Aug;9(4):359-72. doi: 10.1093/humupd/dmg024.
Obesity, particularly the abdominal phenotype, is associated with several reproductive disturbances. Whereas mechanisms by which obesity affect fertility are complex and still not completely understood, an important role appears to be played by the presence of a condition of functional hyperandrogenism and hyperinsulinaemia, which accompanies the insulin-resistant state. In women with the polycystic ovary syndrome, abdominal obesity may be co-responsible for the development of hyperandrogenism and associated chronic anovulation, through mechanisms primarily involving the insulin-mediated overstimulation of ovarian steroidogenesis and decreased sex hormone-binding globulin blood concentrations. By these mechanisms, obesity may also favour resistance to clomiphene and gonadotrophin-induced ovulation and reduce outcomes of IVF/ICSI procedures. Due to the beneficial effects of weight loss, lifestyle intervention programmes should represent the first-line approach in the treatment of infertile obese women. Insulin-sensitizing agents may add further benefits, particularly if administered in combination with hypocaloric dieting. Therefore, individualized pharmacological support aimed at favouring weight loss and improving insulin resistance should be widely extended in clinical practice in obese infertile patients. This may be beneficial even during pregnancy, thereby permitting favourable physiological delivery and healthy babies.
肥胖,尤其是腹型肥胖,与多种生殖功能紊乱有关。虽然肥胖影响生育能力的机制复杂且尚未完全明了,但伴有胰岛素抵抗状态的功能性高雄激素血症和高胰岛素血症似乎起着重要作用。在多囊卵巢综合征女性中,腹型肥胖可能通过主要涉及胰岛素介导的卵巢类固醇生成过度刺激和性激素结合球蛋白血浓度降低的机制,共同导致高雄激素血症和相关的慢性无排卵。通过这些机制,肥胖还可能导致对克罗米芬和促性腺激素诱导排卵的抵抗,并降低体外受精/卵胞浆内单精子注射(IVF/ICSI)程序的成功率。鉴于体重减轻的有益作用,生活方式干预计划应作为肥胖不孕女性治疗的一线方法。胰岛素增敏剂可能会带来更多益处,尤其是与低热量饮食联合使用时。因此,旨在促进体重减轻和改善胰岛素抵抗的个体化药物支持应在肥胖不孕患者的临床实践中广泛应用。这甚至在怀孕期间也可能有益,从而实现顺利的生理分娩和健康的婴儿。